Edition:
India

GlaxoSmithKline Posts Q2 Adjusted EPS 30.5 Pence


Wednesday, 24 Jul 2019 

July 24 (Reuters) - Glaxosmithkline Plc ::Q2 ADJUSTED EPS ROSE 9 PERCENT TO 30.5 PENCE.QTRLY TOTAL EPS 19.5P.2019 ADJUSTED EPS GUIDANCE IMPROVED TO EXPECTED DECLINE OF -3% TO -5% AT CER FROM -5% TO -9%.19P DIVIDEND DECLARED FOR QUARTER; CONTINUE TO EXPECT 80P FOR FY19.QTRLY GROUP SALES £7.8 BILLION, +7% AER, +5% CER.QTRLY ADJUSTED EPS 30.5P.NEW GUIDANCE REFLECTS IMPROVED OPERATING PERFORMANCE, LOWER INTEREST EXPENSE, ONE-OFF BENEFIT TO SHARE OF AFTER TAX PROFITS OF ASSOCIATES IN Q1.QTRLY PHARMACEUTICALS SALES £4.3 BILLION, +2% AER, -1% CER.POSITIVE CLINICAL DATA RECEIVED SO FAR THIS YEAR OFFER SIGNIFICANT NEW OPPORTUNITIES FOR PRODUCTS IN ONCOLOGY, HIV, RESPIRATORY.QTRLY VACCINES SALES £1.6 BILLION, +26% AER, +23% CER.SHINGRIX RECORDED SALES OF £386 MILLION IN THE QUARTER, DRIVEN BY CONTINUED STRONG UPTAKE IN THE US.QTRLY CONSUMER HEALTHCARE SALES £1.9 BILLION, +5% AER, +4% CER.IF EXCHANGE RATES HOLD AT CLOSING RATES ON 30 JUNE FOR REST OF 2019, ESTIMATED POSITIVE IMPACT ON 2019 STERLING TURNOVER GROWTH TO BE ABOUT 2%.EXPECT TO COMPLETE JOINT VENTURE WITH PFIZER SHORTLY.QTRLY TURNOVER INCREASED 5% CER WITH CER GROWTH DELIVERED BY VACCINES, CONSUMER HEALTHCARE PARTIALLY OFFSET BY DECLINE IN PHARMACEUTICALS.QTRLY HIV SALES £1.2 BILLION +2% AER, -2% CER.QTRLY SALES OF ESTABLISHED PHARMACEUTICALS DECLINED 6% AER, 7% CER TO £2,138 MILLION INCLUDING IMPACT OF LOSS OF EXCLUSIVITY OF ADVAIR.TOTAL MAJOR RESTRUCTURING CHARGES INCURRED IN QUARTER WERE £309 MILLION (Q2 2018: £158 MILLION).